Advances in PCL, PLA, and PLGA-Based Technologies for Anticancer Drug Delivery
Pharmaceutics · 20.10.2025 · 17 (10) · 1354
DOI: 10.3390/pharmaceutics17101354 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceutics, online erschienen am 20.10.2025. Verfasst von Yeongbeom Kim und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Smart Health Science and Technology, Kangwon National University, Chuncheon 24341, Republic of Korea. Die Arbeit wurde bisher 63-mal zitiert (Crossref) und nennt 150 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the National Research Foundation of Korea, Bio&Medical Technology Development Program of the National Research Foundation of Korea, NRF of Korea.
Abstract (Originalsprache)
Biodegradable polymers such as Polycaprolactone (PCL), Polylactic acid (PLA), and Poly(lactic-co-glycolic acid) (PLGA) are attracting attention as key platforms for anticancer drug delivery systems due to their excellent biocompatibility and controllable degradation rates. These polymers can overcome limitations of existing chemotherapeutics, such as low bioavailability, systemic toxicity, and nonspecific cell damage, and contribute to the development of precision medicine approaches and long-acting therapeutics. This paper discusses the chemical and physicochemical properties of these three polymers, their synthetic strategies, and the controlled drug release technology through surface functionalization and stimuli-responsive design. Furthermore, we highlight their potential for use in various formulations, including micelles, nanoparticles, hydrogels, and microspheres, enabling enhanced drug solubility, sustained release, and tumor targeting. Preclinical and clinical applications demonstrate that these polymer-based DDSs represent a promising approach for implementing next-generation precision anticancer treatment strategies, with further potential for clinical translation and widespread adoption.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Smart Health Science and Technology, Kangwon National University, Chuncheon 24341, Republic of Korea.
- Department of Biotechnology and Bioengineering, College of ACE, Kangwon National University, Chuncheon 24341, Republic of Korea.
- Institute of Fermentation of Brewing, Kangwon National University, Chuncheon 24341, Republic of Korea.
- Department of Biomedical Engineering, College of Engineering, University of North Texas, Denton, TX 76203-5017, USA.
ORCID-Profile: Yeongbeom Kim, Minyeong Lim, Su Yeon Lim, Suk-Jin Ha, Young-Wook Won, Hyun-Ouk Kim, Kwang Suk Lim
Förderung
- the National Research Foundation of Korea
- Bio&Medical Technology Development Program of the National Research Foundation of Korea
- NRF of Korea
Zitieren
APA
Kim, Y., Kwak, J., Lim, M., Lim, S. Y., Chae, S., Ha, S. J., Won, Y. W., Kim, H. O., & Lim, K. S. (2025). Advances in PCL, PLA, and PLGA-Based Technologies for Anticancer Drug Delivery. Pharmaceutics, 17(10), 1354. https://doi.org/10.3390/pharmaceutics17101354
Vancouver
Kim Y, Kwak J, Lim M, Lim SY, Chae S, Ha SJ, et al. Advances in PCL, PLA, and PLGA-Based Technologies for Anticancer Drug Delivery. Pharmaceutics. 2025;17(10):1354. doi:10.3390/pharmaceutics17101354
BibTeX
@article{Kim2025,
author = {Kim, Yeongbeom and Kwak, Jaewoo and Lim, Minyeong and Lim, Su Yeon and Chae, Sehyun and Ha, Suk-Jin and Won, Young-Wook and Kim, Hyun-Ouk and Lim, Kwang Suk},
title = {Advances in PCL, PLA, and PLGA-Based Technologies for Anticancer Drug Delivery},
journal = {Pharmaceutics},
year = {2025},
volume = {17},
number = {10},
pages = {1354},
doi = {10.3390/pharmaceutics17101354}
}
EUVIMED